Skip to content
Zydus Life Science logo

Zydus Life Science

Zydus Lifesciences Ltd

ZYDUSLIFE NSE
₹1,200.00 −2.90 (−0.24%)
Market Cap
₹1,19,700 Cr
P/E
28.63
View as Markdown
MCP
Close 20 Nov 2026 ₹1,200.00 1Y +273.35 +29.5%
Start ₹926.65

Key Fundamentals

LargecapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
21.10%
Debt to Equity
0.50
EPS (TTM)
₹41.92
Book Value
₹278.88
Market Cap
₹1,19,700 Cr
P/E (TTM)
28.63
P/B
4.30
ROE
21.20%
Dividend Yield
0.08%
EBITDA
₹8,985 Cr
52W High
₹1,266.60
52W Low
₹835.50
Day Range
₹1,193.50 – ₹1,208.50
Volume
7,80,371

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Zydus Life Science peer comparison
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
Zydus Life Science (this company)
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
Median 7 companies1,884.9041.441,23,9805.070.57%16.50%17.80%28,1392,855

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

47 Average

Data confidence 100/100

insider_selling

Category scores

Quality
36
Poor
Returns, margins, earnings quality 22% weight
Valuation
61
Good
Cheap vs sector & own history 24% weight
Growth
73
Strong
Sales & profit trajectory 9% weight
Financial Health
31
Poor
Solvency, leverage, coverage 9% weight
Momentum
39
Weak
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has delivered good profit growth of 18.8% CAGR over last 5 years

No weaknesses listed

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3610
OscillatorsBullish162
Moving AveragesStrong Bullish208

Key readings

RSI (14)
54.44
Neutral
MACD (12,26,9)
10.94
Bearish
SMA (50)
1,166.18
Bullish
SMA (200)
1,056.53
Bullish

As of

Analyst Rating

Based on 29 analysts
BUY52%

15 of 29 analysts rate Buy, 8 Hold, 6 Sell.

As of

BUY
15
52%
HOLD
8
28%
SELL
6
21%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+11.16%
5Y+13.51%
3Y+16.35%
1Y+16.81%
TTM+24.02%

Net profit

Net profit growth by window
10Y+10.06%
5Y+18.59%
3Y+34.80%
1Y+9.65%
TTM−14.45%

Operating cash flow

Operating cash flow growth by window
10Y+1.12%
5Y−8.46%
3Y−7.66%
1Y−68.78%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+6.48 pp
5Y+7.68 pp
3Y+8.83 pp
1Y+0.85 pp
TTM−4.13 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹9,376 Cr
Mar 2018₹11,905 Cr
Mar 2019₹13,166 Cr
Mar 2020₹14,253 Cr
Mar 2021₹14,404 Cr
Mar 2022₹15,110 Cr
Mar 2023₹17,237 Cr
Mar 2024₹19,547 Cr
Mar 2025₹23,242 Cr
Mar 2026₹27,148 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹1,517 Cr
Mar 2018₹1,810 Cr
Mar 2019₹1,899 Cr
Mar 2020₹1,204 Cr
Mar 2021₹2,185 Cr
Mar 2022₹4,618 Cr
Mar 2023₹2,092 Cr
Mar 2024₹3,973 Cr
Mar 2025₹4,673 Cr
Mar 2026₹5,124 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹1,792 Cr −5.6% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 17 Nov 2026
AI opinion · based on fundamentals
Risk medium

Zydus Lifesciences trades at ₹1,204.2 as of 2026-11-17 with a market cap of ₹1,20,119 crore and a P/E of 28.73x. The company has delivered strong compounded sales growth of 14% over five years and profit CAGR of 18.8% over the same period, though TTM profit growth has turned negative at -10% even as TTM revenue growth accelerated to 24%.

Bull Case 8
  • Strong long-term profit growth with 18.8% CAGR over the last five years, well above the broader pharma sector average
  • TTM revenue growth of 24% indicates robust top-line momentum and potential market share gains
  • Consistent return on equity averaging 21% over the last three and five years, reflecting efficient capital deployment
  • ROCE of 19.24% signals healthy returns on total capital employed, supporting reinvestment capacity
  • Manageable leverage with a debt-to-equity ratio of just 0.42, providing financial flexibility for future expansion or acquisitions
  • Stock has delivered a 1-year CAGR of 30% and a 5-year CAGR of 21%, demonstrating sustained investor confidence
  • Compounded sales growth of 16% over three years and 14% over five years shows a durable revenue trajectory across cycles
  • Trading roughly 5% below its 52-week high of ₹1,266.6, indicating the stock has held near peak levels rather than correcting sharply
Bear Case 5
  • TTM profit growth has turned negative at -10% despite 24% revenue growth, suggesting margin compression or one-off cost pressures
  • P/E of 28.73x is elevated for a company whose most recent profit trend is declining, raising questions about valuation sustainability
  • Dividend yield of just 0.08% offers negligible income return, making the stock almost entirely dependent on capital appreciation
  • The divergence between 24% TTM sales growth and -10% TTM profit growth points to deteriorating operating leverage or rising input costs
  • 10-year compounded profit growth of 11% is materially lower than the recent 3-year figure of 32%, suggesting recent gains may not be structurally sustainable

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

20h ago

TL;DR: Zydus is executing an aggressive diversification strategy with Rs 136 billion invested in capex and acquisitions over FY24-26, highlighted by the Sterling Biotech API acquisition and Sunshine Healthcare JV. The standout positive is saroglitazar's strong Phase 2b MASH data, which opens a large therapeutic opportunity. The key risk is the 5 FDA observations at the Moraiya facility (45% of US sales), which requires swift remediation to avoid escalation to a Warning Letter. The trend is net positive given pipeline momentum and analyst upgrades, but regulatory remediation progress will be a near-term overhang to watch.

Headwinds 2
  • US FDA flags Moraiya facility Oct 26

    US FDA issued 5 observations after Oct 5-13 inspection citing data integrity gaps, inadequate investigation of a metal shaving in a tablet (Class II recall), and batches released exceeding assay control limits. Moraiya accounts for ~45% of US sales.

  • LIC reduces stake significantly Nov 6

    LIC cut its holding in Zydus Lifesciences to 3.184% after selling 20,242,068 shares in the open market between August 2025 and November 2026.

Positives 4
  • Saroglitazar MASH Phase 2b success Nov 6

    Saroglitazar 4mg achieved 39.1% steatohepatitis resolution vs 13.7% placebo (P=0.002) in a 189-patient Phase 2b trial over 52 weeks, with no significant weight gain or liver injury signal. Results support advancement to larger studies.

  • Sterling Biotech API deal closed Nov 2

    Zydus completed acquisition of Sterling Biotech's API business on November 2, 2026, after fulfillment of all conditions precedent.

  • Sunshine Healthcare JV finalized Nov 12

    Zydus subscribed to 50% equity in ZyduS Sunshine joint venture with Sunshine Healthcare Lanka on November 11, 2026.

Neutral 3
  • New auditor Walker Chandiok appointed Nov 4

    Walker Chandiok & Co LLP appointed as statutory auditors for a 5-year term starting FY27, replacing Deloitte under mandatory rotation rules.

  • Christoph Stoller heads international Oct 31

    Christoph Stoller appointed President and BU Head for International Markets, succeeding Dr. Amrut Naik who resigned effective November 7, 2026.

  • Investor conference participation Nov 5

    Zydus Lifesciences scheduled to participate in investor conferences in Mumbai on November 17 and November 18, 2026.

Quarterly Results

₹ Cr
ZYDUSLIFE quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
4,369
4,505
5,534
6,208
5,237
5,269
6,528
6,574
6,123
6,864
7,587
8,017
7,910
Expenses
3,223
3,403
3,903
4,124
3,776
3,882
4,402
4,485
4,107
5,048
5,033
6,088
6,015
Operating Profit
1,146
1,102
1,630
2,084
1,461
1,388
2,126
2,088
2,016
1,816
2,554
1,929
1,894
OPM %
26%
24%
29%
34%
28%
26%
33%
32%
33%
26%
34%
24%
24%
Other Income
54
37.7
156
63
68
57
80.6
155
109
26
134
126
159
Interest
9
20
35
32
25
32
77
85
101
130
123
156
187
Depreciation
184
195
205
215
234
229
238
238
302
360
508
530
605
Exceptional Items
—
—
—
—
—
—
−220
—
−34.2
—
−398
—
—
PBT
1,007
926
1,547
1,900
1,271
1,184
1,672
1,921
1,687
1,353
1,660
1,369
1,262
Tax %
22%
23%
21%
23%
29%
15%
25%
23%
27%
29%
19%
26%
26%
Net Profit
803
790
1,246
1,482
920
1,026
1,244
1,521
1,239
1,023
1,341
1,011
928
EPS (₹)
7.91
7.80
11.75
14.11
9.06
10.17
11.64
14.58
12.51
10.36
12.65
9.63
9.28
YoY Sales growth
6
6
10
21
20
17
18
6
17
30
16
22
29

Profit & Loss

₹ Cr
ZYDUSLIFE profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
8,651
9,427
9,376
11,905
13,166
14,253
14,404
15,110
17,237
19,547
23,242
27,148
30,378
Expenses
6,896
7,095
7,474
9,074
10,174
11,455
11,013
11,768
13,378
14,163
16,183
18,673
22,183
Operating Profit
1,756
2,332
1,902
2,831
2,991
2,798
3,391
3,342
3,860
5,384
7,058
8,475
8,195
OPM %
20%
25%
20%
24%
23%
20%
24%
22%
22%
28%
30%
31%
27%
Other Income
45
112
127
111
183
−264
−231
2,581
−422
293
270
510
48
Interest
68
53
45
91
194
342
159
127
130
81
166
439
596
Depreciation
287
292
373
539
599
696
670
713
723
764
916
1,408
2,002
Exceptional Items
—
—
—
—
—
—
—
—
—
—
−220
−517
—
PBT
1,446
2,099
1,612
2,312
2,382
1,495
2,331
5,084
2,585
4,832
6,027
6,621
5,644
Tax %
18%
8%
8%
24%
22%
21%
8%
10%
23%
20%
23%
24%
—
Net Profit
1,188
1,964
1,517
1,810
1,899
1,204
2,185
4,618
2,092
3,973
4,673
5,124
4,302
EPS (₹)
11.24
18.89
14.53
17.35
18.06
11.49
20.84
43.83
19.37
38.36
44.97
50.09
41.92
Div. Payout %
21%
17%
22%
20%
19%
30%
17%
6%
31%
8%
24%
2%
—
Sales growth
20
9
−1
27
11
8
1
5
14
13
19
17
24

Balance Sheet

₹ Cr
ZYDUSLIFE balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
102
102
102
102
102
102
102
102
101
101
101
101
100
Reserves
4,149
5,597
6,858
8,642
10,284
10,273
12,890
16,897
17,415
19,729
23,852
27,011
27,718
Borrowings
2,651
2,442
5,207
5,407
7,899
7,986
4,608
4,221
1,195
804
3,213
12,496
13,966
Other Liabilities
2,144
2,208
2,937
3,632
4,945
5,115
6,165
6,421
6,851
8,201
9,523
11,065
13,823
Total Liabilities
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
55,607
Fixed Assets
3,352
3,748
5,755
6,483
12,164
12,230
12,133
12,188
11,521
12,368
13,134
24,106
27,698
CWIP
798
951
1,543
1,527
837
742
783
726
1,201
2,423
2,692
3,698
1,636
Investments
154
416
435
746
674
765
830
3,288
1,547
1,220
6,412
7,540
8,348
Other Assets
4,743
5,235
7,371
9,028
9,556
9,740
10,019
11,439
11,294
12,822
14,451
15,328
17,925
Total Assets
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
55,607

Cash Flow

₹ Cr
ZYDUSLIFE cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
994
1,894
1,312
919
1,282
2,932
3,294
2,104
2,689
3,196
6,781
2,117
Investing
−465
−860
−2,872
−974
−3,977
−1,004
−837
−1,018
1,542
−1,492
−8,363
−7,895
Financing
−351
−935
2,316
52
1,885
−1,528
−2,548
−868
−4,400
−1,779
1,995
5,807
Net Cash Flow
178
99
756
−3
−811
399
−90
219
−170
−75
414
28
Free Cash Flow
498
936
−1,623
−116
236
2,043
2,447
1,050
1,697
2,313
5,139
−530
CFO/EBITDA
79
109
81
54
65
116
107
83
85
83
122
44

Ratios

ZYDUSLIFE financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
67
68
89
98
110
94
79
81
94
97
64
73
Inventory Days
175
158
193
211
208
207
246
245
197
202
227
282
Days Payable
125
154
165
167
149
152
168
141
123
125
131
142
Cash Conversion Cycle
118
71
116
142
169
149
158
185
168
175
160
212
Working Capital Days
6
−1
−34
17
10
−19
−6
20
70
88
3
−40
ROCE %
23%
28%
16%
18%
15%
11%
14%
13%
15%
22%
24%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Zydus Life Science insights

72 extracted metrics across FY06–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 75.01%
  • DIIs 11.28%
  • FIIs 7.05%
  • Public 5.30%
  • Others 1.36%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Zydus Life Science

What does Zydus Lifesciences Ltd do?
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Where is Zydus Lifesciences Ltd (ZYDUSLIFE) listed?
Zydus Lifesciences Ltd trades as ZYDUSLIFE on the NSE and under code 532321 on the BSE.
Which sector does Zydus Lifesciences Ltd belong to?
Zydus Lifesciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a market capitalisation of ₹1,19,700 Cr as of 20 Nov 2026, which places it in the Largecap band.
What is the PE ratio of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd trades at a PE ratio of 28.63 as of 20 Nov 2026, on earnings per share of ₹41.92, against a book value of ₹278.88 per share.
What is the 52-week high and low of Zydus Lifesciences Ltd?
Over the last 52 weeks Zydus Lifesciences Ltd has traded between ₹835.5 and ₹1,266.6 as of 20 Nov 2026.
Does Zydus Lifesciences Ltd pay dividends?
Zydus Lifesciences Ltd has a dividend yield of 0.08%.
What is the Return on Equity (ROE) of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd reported a return on equity of 21.20%. Its debt-to-equity ratio is 0.50.

Company Information

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

CEO Dr. Sharvil Pankajbhai Patel
Employees 27,917
Listed 18 Apr 2000
Face Value ₹1
Shares Outstanding 99,75,03,832

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZYDUSLIFE.md for Zydus Lifesciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More